Functional food addressing heart health: Do we have to target the gut microbiota?

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 18, Issue 6, 2015, Pages 566-571

  Ryan, Paul M ^a,b   Ross, Reynolds Paul ^c,d   Fitzgerald, Gerald F ^b,c   Caplice, Noel M ^e   Stanton, Catherine ^a,c  

^a TEAGASC FOOD RESEARCH CENTRE   (Ireland)

^b School of Microbiology   (India)

^c UNIVERSITY COLLEGE CORK   (Ireland)

^d LOUISIANA STATE UNIVERSITY   (United States)

^e UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

archeabiotic; atherosclerosis; bile salt hydrolase; exopolysaccharide; trimethylamine N oxide

Indexed keywords

ARABINOXYLAN; BETAINE; CARNITINE; CHOLINE; CHYLOMICRON; PHOSPHATIDYLCHOLINE; PROBIOTIC AGENT; PREBIOTIC AGENT;

BIFIDOBACTERIUM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DYSLIPIDEMIA; FUNCTIONAL FOOD; HUMAN; HYPERCHOLESTEROLEMIA; INTESTINE FLORA; LACTOBACILLUS PARACASEI; LACTOBACILLUS REUTERI; LIPID METABOLISM; NONHUMAN; REVIEW; STREPTOCOCCUS THERMOPHILUS; CARDIOVASCULAR DISEASES; HEART; MICROBIOLOGY;

CARDIOVASCULAR DISEASES; FUNCTIONAL FOOD; GASTROINTESTINAL MICROBIOME; HEART; HUMANS; PREBIOTICS; PROBIOTICS;

EID: 84944070990     PISSN: 13631950     EISSN: 14736519     Source Type: Journal    
DOI: 10.1097/MCO.0000000000000224     Document Type: Review

References (67)

1. Charo IF, Taub R. Anti-inflammatory therapeutics for the treatment of atherosclerosis. Nat Rev Drug Discov 2011; 10:365-376.
2. Bentzon JF, Otsuka F, Virmani R, et al. Mechanisms of plaque formation and rupture. Circ Res 2014; 114:1852-1866.
3. Koeth RA, Wang Z, Levison BS, et al. Intestinal microbiota metabolism of lcarnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 2013; 19:576-585.
4. Tang WHW, Wang Z, Levison BS, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 2013; 368:1575-1584.
5. Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011; 472:57-63.
6. Backhed F. Meat-metabolizing bacteria in atherosclerosis. Nat Med 2013; 19:533-534.
7. Bennett BJ, de Aguiar Vallim TQ, Wang Z, et al. Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab 2013; 17:49-60.
8. Tang W, Hazen SL. The contributory role of gut microbiota in cardiovascular disease. J Clin Invest 2014; 124:4204-4211.
9. Warrier M, Shih DM, Burrows AC, et al. The TMAO-generating enzyme flavin monooxygenase 3 is a central regulator of cholesterol balance. Cell Rep 2015; 10:326-338
10. Karlsson FH, Fa°k F, Nookaew I, et al. Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat Commun 2012; 3:1245.
11. Ras RT, Geleijnse JM, Trautwein EA. LDL-cholesterol-lowering effect of plant sterols and stanols across different dose ranges: A meta-Analysis of randomised controlled studies. Br J Nutr 2014; 112:214-219.
12. Vá squez-Trespalacios EM, Romero-Palacio J. Efficacy of yogurt drink with added plant stanol esters (Benecol(, Colanta) in reducing total and LDL cholesterol in subjects with moderate hypercholesterolemia: A randomized placebo-controlled crossover trial NCT01461798. Lipids Health Dis 2014; 13:1-7.
13. Kriengsinyos W, Wangtong A, Komindr S. Serumcholesterol reduction efficacy of biscuits with added plant stanol ester. Cholesterol 2015; 2015:1-9.
14. De Smet E, Mensink R, Lütjohann D, et al. Acute effects of plant stanol esters on postprandial metabolism and its relation with changes in serum lipids after chronic intake. Eur J Clin Nutr 2014; 69:127-133.
15. Valls R-M, Farras M, Suá rez M, et al. Effects of functional olive oil enriched with its own phenolic compounds on endothelial function in hypertensive patients. A randomised controlled trial. Food Chem 2015; 167:30-35.
16. Merino J, Sala-Vila A, Kones R, et al. Increasing long-chain n-3PUFA consumption improves small peripheral artery function in patients at intermediate-high cardiovascular risk. J Nutr Biochem 2014; 25:642-646.
17. Stepankova R, Tonar Z, Bartova J, et al. Absence of microbiota (germ-free conditions) accelerates the atherosclerosis in ApoE-deficient mice fed standard low cholesterol diet. J Atheroscler Thromb 2010; 17:796-804.
18. Velagapudi VR, Hezaveh R, Reigstad CS, et al. The gut microbiota modulates host energy and lipid metabolism in mice. J Lipid Res 2010; 51:1101-1112.
19. Vine DF, Glimm DR, Proctor SD. Intestinal lipid transport and chylomicron production: possible links to exacerbated atherogenesis in a rodent model of the metabolic syndrome. Atheroscler Suppl 2008; 9:69-76.
20. Jones ML, Tomaro-Duchesneau C, Martoni CJ, et al. Cholesterol lowering with bile salt hydrolase-Active probiotic bacteria, mechanism of action, clinical evidence, and future direction for heart health applications. Expert Opin Biol Ther 2013; 13:631-642.
21. Jones BV, Begley M, Hill C, et al. Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome. Proc Natl Acad Sci U S A 2008; 105:13580-13585.
22. Qi Y, Jiang C, Cheng J, et al. Bile acid signaling in lipid metabolism: metabolomic and lipidomic analysis of lipid and bile acid markers linked to antiobesity and antidiabetes in mice. Biochim Biophys Acta 2015; 1851:19-29.
23. Zwicker BL, Agellon LB. Transport and biological activities of bile acids. Int J Biochem Cell Biol 2013; 45:1389-1398.
24. de Aguiar Vallim TQ, Tarling EJ, Edwards PA. Pleiotropic roles of bile acids in metabolism. Cell Metab 2013; 17:657-669.
25. Hageman J, Herrema H, Groen AK, et al. A role of the bile salt receptor FXR in atherosclerosis. Arterioscler Thromb Vasc Biol 2010; 30:1519-1528.
26. Degirolamo C, Rainaldi S, Bovenga F, et al. Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr-Fgf15 axis in mice. Cell Rep 2014; 7:12-18.
27. Jones ML, Tomaro-Duchesneau C, Prakash S. The gut microbiome, probiotics, bile acids axis, and human health. Trends Microbiol 2014; 22:306-308.
28. Sayin SI, Wahlström A, Felin J, et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metal 2013; 17:225-235.
29. Kumar R, Grover S, Batish VK. Hypocholesterolaemic effect of dietary inclusion of two putative probiotic bile salt hydrolase-producing Lactobacillus plantarum strains in Sprague-Dawley rats. Br J Nutr 2011; 105:561-573.
30. Joyce SA, MacSharry J, Casey PG, et al. Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut. Proc Natl Acad Sci 2014; 111:7421-7426.
31. Jones ML, Martoni CJ, Parent M, et al. Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-Active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults. Br J Nutr 2012; 107:1505-1513.
32. Qin G, Tu J, Zhang C, et al. The value of the apoB/apoAI ratio and the non-HDL-C/HDL-C ratio in predicting carotid atherosclerosis among Chinese individuals with metabolic syndrome: A cross-sectional study. Lipids Health Dis 2015; 14:1-8.
33. Walldius G, Jungner I. The apoB/apoAI ratio: A strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy-A review of the evidence. J Intern Med 2006; 259:493-519.
34. Jones ML, Martoni CJ, Prakash S. Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: A randomized controlled trial. Eur J Clin Nutr 2012; 66:1234-1241.
35. Jones ML, Martoni CJ, Prakash S. Oral supplementation with probiotic L. reuteri NCIMB 30242 increases mean circulating 25-hydroxyvitamin D: A post hoc analysis of a randomized controlled trial. J Clin Endocrinol Metabol 2013; 98:2944-2951.
36. Sypniewska G, Pollak J, Strozecki P, et al. 25-Hydroxyvitamin D, biomarkers of endothelial dysfunction and subclinical organ damage in adults with hypertension. Am J Hypertens 2014; 27:114-121.
37. Ryan PM, Ross RP, Fitzgerald GF, et al. Sugar-coated: exopolysaccharide producing lactic acid bacteria for food and human health applications. Food Funct 2015; 6:679-693.
38. London LE, Kumar AH, Wall R, et al. Exopolysaccharide-producing probiotic lactobacilli reduced serum cholesterol and modified enteric microbiota in ApoE-deficient mice. J Nutr 2015; 144:1956-1962.
39. Stack HM, Kearney N, Stanton C, et al. Association of beta-glucan endogenous production with increased stress tolerance of intestinal lactobacilli. Appl Environ Microbiol 2010; 76:500-507.
40. Lindstrom C, Holst O, Nilsson L, et al. Effects of Pediococcus parvulus 2.6 and its exopolysaccharide on plasma cholesterol levels and inflammatory markers in mice. AMB Express 2012; 2:66.
41. David LA, Maurice CF, Carmody RN, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014; 505:559-563.
42. Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol 2014; 12:661-672.
43. Demigné C, Morand C, Levrat M-A, et al. Effect of propionate on fatty acid and cholesterol synthesis and on acetate metabolism in isolated rat hepatocytes. Br J Nutr 1995; 74:209-219.
44. Puertollano E, Kolida S, Yaqoob P. Biological significance of short-chain fatty acid metabolism by the intestinal microbiome. CurrOpin Clin NutrMetab Care 2014; 17:139-144.
45. Neyrinck AM, Van Hee V, Piront N, et al. Wheat-derived arabinoxylan oligosaccharides with prebiotic effect increase satietogenic gut peptides and reduce metabolic endotoxemia in diet-induced obese mice. Nutr Diabetes 2012; 2:e28.
46. Everard A, Cani PD. Diabetes, obesity and gut microbiota, best practice & research. Clin Gastroenterol 2013; 27:73-83.
47. Everard A, Lazarevic V, Derrien M, et al. Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. Diabetes 2011; 60:2775-2786.
48. Tolhurst G, Heffron H, Lam YS, et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 2012; 61:364-371.
49. Xiao C, Bandsma RH, Dash S, et al. Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans. Arterioscler Thromb Vasc Biol 2012; 32:1513-1519.
50. Xiao C, Dash S, Morgantini C, et al. New and emerging regulators of intestinal lipoprotein secretion. Atherosclerosis 2014; 233:608-615.
51. Xiao C, Dash S, Morgantini C, et al. Sitagliptin, a DPP-4 inhibitor, acutely inhibits intestinal lipoprotein particle secretion in healthy humans. Diabetes 2014; 63:2394-2401.
52. Farr S, Baker C, Naples M, et al. Central nervous system regulation of intestinal lipoprotein metabolism by glucagon-like peptide-1 via a brain-gut axis, arteriosclerosis. Thromb Vasc Biol 2015; 35:1092-1100.
53. Tong L-T, Zhong K, Liu L, et al. Effects of dietary wheat bran arabinoxylans on cholesterol metabolism of hypercholesterolemic hamsters. Carbohydr Polym 2014; 112:1-5.
54. Kim M, Platt MJ, Shibasaki T, et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med 2013; 19:567-575.
55. Buglioni A, Burnett JC Jr. A gut-heart connection in cardiometabolic regulation. Nat Med 2013; 19:534-536.
56. Pachikian BD, Neyrinck AM, Cani PD, et al. Hepatic steatosis in n-3 fatty acid depleted mice: focus on metabolic alterations related to tissue fatty acid composition. BMC Physiol 2008; 8:1-11.
57. Pachikian BD, Essaghir A, Demoulin JB, et al. Prebiotic approach alleviates hepatic steatosis: implication of fatty acid oxidative and cholesterol synthesis pathways. Mol Nutr Food Res 2013; 57:347-359.
58. Catry E, Rath G, Pachikian BD, et al. Prebiotics supplementation improves the endothelial dysfunction in n-3 PUFA-depleted ApoE-/-mice. Arch Public Health 2014; 72:O5.
59. Catry E, Pachikian BD, Neyrinck AM, et al. Prebiotics supplementation improves the endothelial dysfunction induced by a nutritional deficiency in n-3 polyunsaturated fatty acids (PUFA). Arch Cardiovasc Dis Suppl 2015; 7:137.
60. Hoffmann C, Dollive S, Grunberg S, et al. Archaea and fungi of the human gut microbiome: correlations with diet and bacterial residents. PLoS One 2013; 8:e66019.
61. Jarrell KF, Walters AD, Bochiwal C, et al. Major players on the microbial stage: why archaea are important. Microbiology 2011; 157:919-936.
62. Pimentel M, Gunsalus RP, Rao SS, et al. Methanogens in human health and disease. Am J Gastroenterol Suppl 2012; 1:28-33.
63. Aminov RI. Role of archaea in human disease. Front Cell Infect Microbiol 2013; 3:42.
64. Brugère J-F, Borrel G, Gaci N, et al. Archaebiotics: proposed therapeutic use of archaea to prevent trimethylaminuria and cardiovascular disease. Gut Microbes 2014; 5:5-10.
65. Gaci N, Borrel G, Tottey W, et al. Archaea and the human gut: new beginning of an old story. World J Gastroenterol 2014; 20:16062-16078.
66. Mihajlovski A, Doré J, Levenez F, et al. Molecular evaluation of the human gut methanogenic archaeal microbiota reveals an age-Associated increase of the diversity. Environ Microbiol Rep 2010; 2:272-280.
67. Fernandes J, Wang A, Su W, et al. Age, dietary fiber, breath methane, and fecal short chain fatty acids are interrelated in Archaea-Positive humans. J Nutr 2013; 143:1269-1275.